Nicotine, propylene glycol and tobacco-specific nitrosamines content in selected e-liquids in Malaysia: the case support for initiation of standards or guidelines by Zulkifli, Aziemah et al.
Mal J Med Health Sci 14(SP2): 95-103, Nov 2018 95
Malaysian Journal of Medicine and Health Sciences (eISSN 2636-9346)
ORIGINAL ARTICLE
Nicotine, Propylene Glycol and Tobacco-specific Nitrosamines 
Content in Selected E-Liquids in Malaysia: The Case Support for 
Initiation of Standards or Guidelines  
Aziemah Zulkifli1, Emilia Zainal Abidin1, Najihah Zainol Abidin1, Hasanah Mohd Ghazali2, Sarva Mangala 
Praveena1, Amer Siddiq Amer Nordin3, Sharifah Norkhadijah Syed Ismail1, Irniza Rasdi1, Karmegam 
Karuppiah1, Anita Abd Rahman4, Zuraidah Musbah1, and Nur Fadhilah Zulkipli1
1  Department of Environmental and Occupational Health, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 
43400 Serdang, Selangor, Malaysia
2 Department of Food Science, Faculty of Food Science and Technology, Universiti Putra Malaysia, 43400 Serdang, Selangor, 
Malaysia. 
3   University Malaya Centre of Addiction Sciences (UMCAS), University Malaya, 50603 Kuala Lumpur, Malaysia. 
4   Department of Community Health, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, 
Selangor, Malaysia
ABSTRACT
Introduction: Electronic Cigarette (EC) usage has been gaining acceptance in Malaysia despite its lack of analytical 
evidence on the chemical constituents of its liquid formulations. This study aims to evaluate the chemical concen-
trations of nicotine, propylene glycol (PG) and selected Tobacco-Specific Nitrosamines (TSNAs); 4-(methylnitrosa-
mino)-1-(3-pyridyl)-1-butanone (NNK) and N’-nitrosonornicotine (NNN) in e-liquids locally sourced from the Ma-
laysian market. Methods: A total of 17 e-liquids from a variety of flavours and brands were purchased from local EC 
retailers in Klang Valley, Malaysia. Nicotine and PG concentrations were assessed using Gas Chromatography-Flame 
Ionization Detector (GC-FID) while NNK and NNN were quantified using Liquid Chromatography-Tandem Mass 
Spectrometry (LC-MS/MS). The concentrations of nicotine and PG (mg/mL) were described in comparison with the 
levels indicated on the labels when present while levels of TSNAs were descriptively explained. Results: Nicotine 
was detected in all e-liquid samples, despite several samples being declared as nicotine-free. The average (standard 
deviation) level of nicotine, PG, NNN and NNK were 3.26 (1.04) mg/mL, 484.10 (98.24) mg/mL, 0.383(0.288) µg/L 
and 0.086 (0.057) µg/L, respectively. Labelling discrepancies (when indicated on the label) of nicotine and PG were 
between the range of 27%-73% and 3%-63%, respectively. Conclusion: The concentrations of nicotine and PG 
in local e-liquids were varied. There were evidences of labelling discrepancy in that local e-liquids. TSNAs were 
detected in all samples of e-liquids. This study brought forth strong evidence on the need for the implementation of 
regulation on e-liquid manufacturing and sales, particularly on the accuracy of labelling and licensing to protect the 
public health.
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The use of electronic cigarettes (EC) have grown 
exponentially over the past few years and has been one 
of the most used innovation of tobacco products (1,2). 
EC works by delivering nicotine in aerosolised form. 
Once the sensor in the mouthpiece detects airflow, it 
activates a heating element that surrounds the cotton 
wick soaked with EC solution known as electronic-liquid 
(e-liquid) which often contains nicotine. This results in 
the vaporising of nicotine into aerosolised  form that are 
later inhaled by the users (3,4). 
Two major ingredients of e-liquid are propylene glycol 
(PG) and glycerine which are responsible in producing 
aerosols also act as a solvent for flavours and colours 
(5,6). Apart from that, e-liquid also contained flavouring 
additives (7) which have been associated with 
respiratory problems. For nicotine, its concentration in 
e-liquids have been found to range between 0.0001 
mg/mL to 0.324 mg/mL (8). In the United Kingdom 
(UK), United States (US) and Poland, nicotine content 
is usually labelled by categories: low, medium or 
high concentrations (3,9). The European Food Safety 
Authority (EFSA) has established an Acute Reference 
Dose (ARfD) of 0.0008 mg/kg body weight according 
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to the Lowest Observed Adverse Effect Level (LOAEL) 
of 0.0035 mg/kg body weight for pharmacological 
effects after intravenous application of nicotine (10). 
While, the allowable maximum level of PG in the fine 
bakery wares and mixes are 1500 mg/kg as regulated in 
international standard for food additives (11). In terms 
of PG’s toxicological profile, a minimal risk level (MRL) 
is 0.009 ppm (6), derived for intermediate-duration (15-
364 days) of inhalation exposure. 
TSNAs which known to be among the most potent 
compound found in tobacco products have also been 
reported to be present in e-liquids at variable levels (12,13). 
Compared to weaker carcinogenic TSNAs namely N’-
nitrosoanabasine (NAT) and N-nitrosoanabasine (NAB), 
NNK and NNN are categorized as group 1 carcinogens 
(14). The latter are commonly found in e-liquids at 
average concentrations of 1.71 (1.69) µg/L for NNK 
and 4.06 (9.34) µg/L for NNN (13) while a median 
(interquartile range, IQR) concentration of 4.7 (3.2-6.8) 
µg/L and 1.3 (0.5-4.4) µg/L respectively, was reported by 
other study (12). 
The use of EC among adult smokers in Malaysia was 
reported within the percentage of 10.4% to 15% (15,16). 
However, there are a lack of comprehensive surveys 
identifying the factors for the high EC usage. Previous 
studies have cited that EC was used as a harm  reduction 
tool for smokers (17,18) but this applies to those with 
higher dependency to nicotine because there is the 
need for EC users to increase their initial nicotine intake 
up to 12 mg/mL before being able to successfully quit 
smoking (19,20). The need for the higher nicotine intake 
was due to low nicotine absorption from EC resulting in 
the ineffective delivery of nicotine to users. On the other 
hand, contrary finding was evident in a systematic meta-
analysis study (21) where the use of EC was significantly 
correlated with lower quitting ratio. Due to the fact that 
nicotine is addictive, the increment of usage among 
youths who were previously non-smokers is a valid 
concern (21-23). 
Globally, there are different EC regulations and policies 
adopted across different countries (23-25). In Malaysia, 
the sale, supply and storage of products containing 
nicotine are regulated under the  Poison Act 1952 
(26), restricting the sales of nicotine-containing EC to 
licensed pharmacies or medical officers only. There 
have been occurrences reported outside of Malaysia 
where e-liquids sold were found to contain detectable 
amounts of nicotine despite being labelled as nicotine-
free (8,27,28). The labelling discrepancy may have 
been intentional to circumvent restriction mandated by 
law. In Malaysia, there is no set of specific standards 
for the manufacturing and packaging of e-liquids or EC. 
Unlike the production of conventional cigarettes (29), 
the manufacturing of e-liquids for the Malaysian market 
is not subjected to any specified standards pertaining to 
its contents and quality assurance of the product apart 
from the restriction in Poison Act. 
There is a lack of published reports available focusing 
on chemical contents of local e-liquids in Malaysia 
despite the significant public health interest to EC and 
the controversial uncertainty regarding the harm due to 
its usage. Thus, this study aims to evaluate the chemical 
concentrations of nicotine, propylene glycol (PG) and 
selected Tobacco-Specific Nitrosamines (TSNAs); 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) 
and N’-nitrosonornicotine (NNN) in e-liquids locally 
sourced from the Malaysian market. This study will 
provide crucial baseline information to narrow down 
the existing scientific gap and assist public health 
professionals and relevant administrative bodies in 
making decisions regarding the manufacturing, sales 
and usage of EC. The information obtained will enable 




A total of 17 locally manufactured e-liquids  of various 
brands (30 mL bottle each) were purchased from three 
local vape retailers located within the Klang Valley, 
Malaysia. The e-liquids were then categorised according 
to its flavours as follows: fruity, coffee, tobacco, creamy 
rosewater syrup (a common flavour local to Malaysia), 
chocolate, creamy, menthol, vanilla and cola. The 
selections were based on the most favoured local 
e-liquids identified from  questionnaire surveys on EC 
usage and patterns of use among 86 adult users in Klang 
Valley, Malaysia (30). The purchased samples were 
assigned with a unique coding, placed in individual zip-
logged bags, kept from light source and were then stored 
at room temperature prior to analysis. 
Reagents 
Nicotine (L-nicotine, (≥99%) and 1,2-propanediols 
(≥99%) respectively) reference standards and 
dichloromethane (DCM) were purchased from Fisher 
Scientific Ltd. (New Jersey, USA). Isopropyl alcohol 
(i-propanol) was purchased from Systerm ChemAR 
(Malaysia). Reference standards of NNN (1mg/mL) 
(KIT0570) 95% and NNK (1mg/mL) (KIT0575) 98%, 
and isotope internals standards of NNN-d4 (0.1mg/
mL) (KIT0765) 98% and NNK-d4 (1mg) (M325751) 
98% were purchased from Toronto Research Chemicals 
(Canada). HPLC grade methanol (MeoH) was purchased 
from J.T. Baker (US). 
Sample preparation and analysis procedures
The analysis of nicotine and PG were carried out based 
on the modification of a previously reported method 
(27). In brief, e-liquid samples were diluted with iso-
propyl alcohol. Due to the wide difference in nicotine 
and PG contents in the e-liquids samples, two dilutions 
were prepared (5df and 250df, respectively) (28) prior to 
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the injection into the GC-FID. A method of liquid-liquid 
extraction for the determination of selected TSNAs level 
was modified from previous study (13). Firstly, 0.5 µL of 
e-liquid sample was pipetted into 20mL test tube and 
4 mL deionized water was added. The solution was 
then extracted twice with 4 mL of dichloromethane by 
mechanical shaking for 10 minutes. The total organic 
phase was evaporated using rotary evaporator for 15 to 20 
minutes. The remaining solution was then filtered using 
syringe filter (0.22 µm membrane pore size). About 380 
µL of the sample was transferred into the autosampler 
vial and diluted with 100 µL of methanol. The addition 
of 20 µL of mix solution of internal standards (40 ppb) 
was added into the autosampler vial. The final volume 
of the sample was 0.5 mL and 25 µL prior automatically 
injected into the LC system. The repeatability (intra-
day measurement) and reproducibility (inter-day 
measurement) test of all compounds were presented in 
Table I. 
Instrumentation and apparatus
The concentration of nicotine and PG were analysed 
using an Agilent HP-624 GC-FID (Agilent Technologies, 
CA, USA). The chromatographic separation was 
accomplished using a J&W Scientific capillary column 
(DB-624, 30m, 0.25 mm i.d., 1.4µm film thickness, Part-
No. 122-1334). For the quantification of nicotine and 
PG contents, a five-point calibration curve ranging from 
0.2 mg/mL to 1 mg/mL was prepared for each analyte. 
Accela high speed Liquid Chromatography interface to 
Thermo Scientific Quantum Ultra triple stage quadrupole 
(QqQ) mass spectrometer (Thermo Scientific, CA, USA) 
was used to quantify the NNK and NNN. The analytes 
were separated using a 3.0 mmx50 mm Poroshell 120, 
Table I: Intra- and inter-day laboratory accuracy and precision results for the analysis of nicotine, PG, and TSNAs (n=5)
Compound Concentration Intra-day measured value (Repeatability) (n=5)
Nicotine
0.6mg/mL
Measured concentration (mg/mL) Accuracy1 (%) Precision2 (%RSD)
0.5971±0.0075 99.516±1.249 1.25
Inter-day measured value (Reproducibility)
Measured concentration (mg/mL) Accuracy (%) Precision (% RSD)
1st day (n=5) 0.5971±0.0075 99.516±1.249 1.25
2nd day (n=5) 0.5782±0.0146 96.361±2.430 2.52
3rd day (n=5) 0.5724±0.0154 95.396±2.566 2.69
PG
Intra-day measured value (Repeatability)(n=5)
0.6mg/mL
Measured concentration (mg/mL) Accuracy (%) Precision 
(% RSD)
0.5367±0.0184 89.449±3.066 3.427
Inter-day measured value (Reproducibility)
Measured concentration (mg/mL) Accuracy (%) Precision (% RSD)
1st day (n=5) 0.5367±0.0184 89.449±3.066 3.427
2nd day (n=5) 0.5318±0.0164 88.640±2.739 3.08
3rd day (n=5) 0.5104±0.0076 85.062±1.270 1.49
Intra-day measured value (Repeatability)
NNK
60µg/L
Measured concentration (µg/L) Accuracy (%) Precision (% RSD)
69.60±6.85 116.00±11.42 9.84
Inter-day measured value (Reproducibility)
Measured concentration (µg/L) Accuracy (%) Precision  (% RSD)
1st day (n=5) 69.60±6.85 116.00±11.42 9.84
2nd day (n=5) 62.78±3.43 104.63±5.72 5.46
3rd day (n=5) 63.59±4.09 105.98±6.82 6.43
NNN
60µg/L
Intra-day measured value (Repeatability)
Measured concentration (µg/L) Accuracy (%) Precision  (% RSD)
67.89±4.06 113.15±6.77 5.98
Inter-day measured value (Reproducibility)
Measured concentration (µg/L) Accuracy (%)     Precision (% RSD)
1st day (n=5) 67.89±4.06 113.15±6.77    5.98
2nd day (n=5) 64.51±3.51 107.52±5.84    5.44
3rd day (n=5) 62.82±6.33 104.71±10.55    10.07
aAccuracy (%):                                                    x 100                               bPrecision (%RSD):                                      x 100measured concentration value 
       true concentration value
Standard deviation,SD
                 Mean
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EC-C18 column with 2.7 µm pore size (Agilent, USA). 
Calibration curves were established for each compound 
containing eight points ranging from 0.5 to 100 µg/L for 
NNK and 1 to 100 µg/L for NNN. The limits of detection 
of NNK and NNN were 0.012µg/L and 0.021µg/L, 
respectively. 
In the absence of certified reference materials, 0.6 mg/
mL of nicotine and PG standard solutions were prepared 
and measured for repeatability (intra-day measurement) 
and reproducibility (inter-day measurement). Intra-
day accuracy (%) and precision (% Relative Standard 
Deviation, % RSD) were evaluated for five injections of 
analyte standard solutions at concentrations of 0.6 mg/
mL in one day. Inter-day accuracy (%) and precision (% 
Relative Standard Deviation, % RSD) were determined 
by their recoveries on three different days. The intra-day 
accuracy for nicotine was 99.5±1.25% and the precision 
was less than 10% (1.25% RSD) whereas , the accuracy 
percentage was reported between the range of 96.36% 
to 99.52% for inter-day analysis.The precision of the 
analysis was 1.25% to 2.69%. The accuracy of intra-day 
measurement for PG analysis showed a good accuracy 
and precision with 89.45±3.07% and 3.43% RSD.
The accuracy and precision of the TSNAs analysis 
were determined by performing intra-day and inter-day 
analysis of 60 µg/L NNK and NNN standards solutions; 
spiked with 40 µg/L internal standards. The intra-day 
analysis for five replicates of injections were resulted 
a good accuracy with an average of 124.57% and 
115.78% for NNK and NNN respectively. While the 
range accuracy for three consecutive days of analysis 
(inter-day) were 104.63-124.57% for NNK and 104.71-
113.15% for NNN.  Table I summarizes the precision 
and accuracy for the determination of nicotine, PG, 
NNK and NNN. 
RESULTS
Nicotine and Propylene Glycol
Descriptively, out of the 17 samples examined in this 
study, seven samples (41%) had no specified nicotine 
concentration on their labels. Eight samples (n=8) were 
labeled to contain 6 mg of nicotine. Another two bottles 
had nicotine-free declared on its label. For samples with 
labeled nicotine concentration, the actual measured 
concentrations were lower by 27% to 73% compared 
to declared-contents. Nicotine was also detected in two 
samples of e-liquids, despite being declared as nicotine-
free. For e-liquids without any indication of nicotine 
content, the nicotine concentrations were found to 
range from 2.07-5.15 mg/mL with mean (standard 
deviation, s.d.) of 3.38 (1.24) mg/mL. The average 
(s.d) content of PG was 484.1(98.2) mg/mL and ranged 
between 316.7 mg/mL to 715.7 mg/mL. Only 12 of the 
samples indicated concentrations of PG on their labels 
(ranging from 34% to 60%). Distributions of PG and 
nicotine concentrations are as presented in Table II.  The 
representative GC chromatograms of nicotine’s standard 
Table II: Concentration of nicotine, PG, NNN and NNK in local-manufactured e-liquids (N=17)
ID





















(%) Measured Content (µg/L)
EL1 Coffee NS1 0 1.80 - 50 487.5 2.50 0.683 0.065
EL2 Tobacco NS 0 3.48 - 35 397.7 13.6 0.415 0.084
EL3 Coffee 30 6 1.60 73.3 NS 448.5 - 0.193 0.031




30 6 3.26 45.67 30 316.7 5.56 0.166 0.070
EL6 Chocolate 32 6 3.62 39.67 34 555.4 63.3 0.868 0.151
EL7 Creamy 30 6 3.55 40.83 40 488.6 22.2 0.147 0.027
EL8 Creamy 30 6 3.65 39.17 30 409.7 36.6 0.979 0.113
EL9 Creamy NS 6 3.99 33.50 60 472.1 21.3 0.316 0.073
EL10 Menthol 30 6 4.41 26.50 50 401.1 19.9 0.727 0.186
EL11 Fruity 30  NS1 2.07 NS NS 515.5 - 0.133 0.072
EL12 Fruity NS NS 2.48 NS NS 715.7 - 0.631 0.141
EL13 Fruity NS NS 2.67 NS 50 416.7 16.7 0.127 0.116
EL14 Menthol NS NS 2.45 NS 50 469.7 6.06 0.188 0.019
EL15 Creamy 30 NS 4.38 NS 60 645.5 7.45 0.042 0.016
EL16 Vanilla 30 NS 4.47 NS 50 419.5 16.1 0.355 0.025
EL17 Cola 30 NS 5.15 NS NS 483.9 - 0.369 0.196
Average3 3.26 (1.04) 484.1 (98.2) 0.383 (0.288) 0.086 (0.057)
1 NS: Not stated; 2 %Difference from label: , 3 Mean (Standard deviation); 4 conversion of % to mg/mL: author has rounded the actual PG density of 1.04g/cm3 to 1.0g/cm3
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Figure 1:  Representative of GC chromatogram of nicotine standard 
solution (5df) (0.6mg/mL)
Figure 2:  Representative of GC chromatograms of sample “EL9” for 
nicotine analysis (5df) 
and e-liquid sample are shown in Figure 1 and Figure 2, 
respectively. 
Tobacco-specific nitrosamines (TSNAs)
All samples had detectable levels of NNN and NNK. 
The mean (s.d) concentration of NNN was 0.383 
(0.288) µg/L while for NNK, the average was 0.085 
(0.057) µg/L. The highest level of NNN (0.980 µg/L) 
and NNK (0.196 µg/L) was found in sample “EL8” and 
“EL17”, respectively. The lowest level of NNN (0.042 
µg/L) and NNK (0.016µg/L) were present in the same 
sample; sample “EL15”. The measured content of NNN 
and NNK are included in Table II. Examples of LC-MS/
MS chromatograms of the selected TSNAs are shown in 
Figure 3 and Figure 4. 
Figure 3:  Representative of LCMS/MS chromatograms of sample “EL17” for NNK analysis 
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DISCUSSION
This study was able to objectively measure the 
concentrations of nicotine, PG and selected TSNAs in 17 
locally-sourced e-liquid purchased in the Klang Valley, 
Malaysia. There are no other local studies thus far which 
have reported the levels of chemical constituents of 
locally made e-liquids, even though the trend of use is 
on the rise. 
This study found inconsistencies between the levels 
of nicotine declared on the labels of e-liquid bottles 
from the actual concentrations measured. Most of the 
e-liquids had lower actual nicotine concentrations 
compared to the levels declared, which is similar to 
findings previously described elsewhere (3,31,32). It is 
suggested that the lower nicotine concentrations may 
be due to the degradation of nicotine over time into 
other nicotine-related substances. One study reported 
that degradation may account up to 4.4% of the total 
nicotine content in e-liquids (33). This study also found 
that e-liquids which were declared as nicotine-free were 
found to contain nicotine. To explain this, it may be 
that the detected nicotine in nicotine-free e-liquids may 
have been carried over from other ingredients which 
Figure 4:  Representative of LCMS/MS chromatograms of sample “EL14” for NNN analysis 
occur during the manufacturing process as reported in 
a previous study (8). If the nicotine were in fact being 
unintentionally carried over, the levels measured will 
likely be in minute concentrations; however in this 
study, the levels were similar to the samples declared 
to contain nicotine; in other words, there were minimal 
differences in terms of the distribution of nicotine, 
meaning most likely that the e-liquids were intentionally 
spiked with specific concentrations of nicotine. This 
finding may suggest that nicotine concentration in local 
e-liquids were purposely undeclared or incorrectly 
labelled in order to circumvent the sale restriction as 
indicated in the existing legislation.
The main concern on incorrect labelling of nicotine is 
the increased likelihood of EC users to be involuntarily 
exposed to higher levels of nicotine. There is the 
possibility that nicotine addiction among novice EC users 
is induced which is against the tobacco control policy 
of this country and nicotine addiction among dual-users 
in worsened (34). In such scenario, the potential of EC 
to be used as a tool for smoking cessation needs to be 
carefully considered.  
The issue of inconsistency in the labelling of e-liquids 
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known to be safe, over consumption and individual 
pattern of EC usage would exacerbate its repercussions 
to the users. 
This study measured TNSAs which are carcinogenic 
compounds produced from the process of nicotine 
extractions from tobacco leaves (4). Insufficient storage 
during manufacturing process have caused the nitrosation 
of nornicotine originated from nicotine that occurs in 
the e-liquid solution (42) and therefore, enhancing NNN 
content in e-liquids. For this study, the measured NNN 
and NNK levels were found to be lower than the level 
reported in a previous study; (14) 1.71(1.69) µg/L for 
NNK and 4.06(9.34) µg/L for NNN. Several studies have 
reported low or undetectable levels of TSNAs (39,40). 
Despite of low detected level of TSNA, the conversion 
of nitrate contained in the e-liquid into nitrite in saliva 
(43) would result in the endogenous production of TSNA 
(44). Thus, the potential carcinogenic health risks will be 
worsened by the additional mechanism taking  place in 
the human body which may result in higher exposures 
to TSNA compounds. 
In summary, this study is among the first published 
data on the analysis of chemical contents in selected 
brands of locally-manufactured e-liquids which is 
currently scarce in Malaysia. The evidence found in this 
study may help to reduce the knowledge gap regarding 
chemical constituents of e-liquids and can be used by 
public health researchers to perform risk estimation 
due to exposures to the chemicals. This study may help 
provide input to the authorities in assisting them to make 
decisions pertaining to the regulating of EC in Malaysia 
as the analysis covered the most used EC brands (34) by 
the local EC users.
There are several limitations in this study; 1) only one 
batch of e-liquids sample was purchased for each 
brand, thus any variation due to different production 
batches was unable to be determined, 2) this study 
had specifically selected e-liquid samples with 6 mg 
of nicotine in its content (when nicotine is declared on 
its label), the lowest in the available range, to reflect 
the common selection of adult smokers reported in a 
previous study used as a reference (30). In retail shops, 
there are options for e-liquids containing 10 or 12 mg 
of nicotine for selection, as such there may be the need 
to also include other range of nicotine concentration in 
future studies.  
CONCLUSION
This study found that the concentrations of nicotine and 
PG in local e-liquids were varied. There were evidence 
of labelling discrepancy and e-liquids declared as 
nicotine-free had in fact contain nicotine. Despite its 
low levels, carcinogenic TSNAs were detected in all 
samples of e-liquids. These findings have brought forth 
evidence on the crucial  need for the implementation 
may also be due to the  unavailability of guideline, 
unlike in other developed countries at present. The 
Ministry of Health has announced they are inclined 
towards prohibiting EC as stipulated by the World Health 
Organisation Framework Convention on Tobacco 
Control (WHO FCTC) (35) but this would require an 
amendment of the legislation. Thus,  the manufacturing 
and sales of e-liquids in the local market continues 
without any clear restrictions. In certain countries, 
manufacturers need to closely adhere to the permissible 
levels of nicotine in e-liquids. There is a need for similar 
stipulation in the regulation; or at minimum, in the 
industrial code of practice for the manufacturers and 
retailers to comply with. 
Taking into considerations the guidelines available 
elsewhere (24,36), the construction of similar outline 
can be seen as a good initial approach to be adapted 
in controlling and managing the production of local-
manufactured e-liquids. This is to prevent any unwanted 
health consequences from intentional EC usage among 
vulnerable populations such as young adolescents 
and women or unintentional e-liquid exposure among 
children such as accidental ingestion (37). Thus, safety 
aspects such as childproof bottles and warning lables 
need to be considered in the production of e-liquids. 
Compared to a previous study in Italy (27) (530.7±11.3 
to 538.7±15.3 mg/mL), e-liquids in this study had 
a lower average of PG. In spite of the non-toxic 
characteristics of PG (6), several studies have shown 
that the heating process of this humectant has been 
proven to produce carcinogenic carbonyl compounds 
such as formaldehyde, acetaldehyde and acrolein in EC 
vapours (3,38). The composition of e-liquids containing 
more PG combined with the high EC battery voltage 
suggested to contribute to a higher amount of carbonyl 
compounds in EC vapour as PG is more prone to thermal 
decomposition than vegetable glycerine (VG), another 
base solution for e-liquids (38).
The acute and chronic exposures to PG have shown to 
cause eye and respiratory irritation and may also affect 
the central nervous system (6). The risk of exposures to PG 
can be further described using Health Risk Assessment 
method as have been previously published (39). The 
calculation of risk can be made using the information on 
vaping topography  of a particular population; combined 
with concentration of PG determined analytically such 
as in this study. The potential Average Daily Dose (ADD) 
of PG can be used for estimating the hazard quotient 
(HQ) which indicates whether PG exposure could 
possibly pose appreciable non-carcinogenic health 
risk to the users. In addition, there are other significant 
factors that influenced the estimated risks such as the 
frequency of  EC usage and the volume of e-liquid 
ingested either after deposition of vapour droplet into 
the upper aero-digestive tract during normal vaping or 
accidental ingestion (40,41). Even though PG has been 
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of regulation on e-liquid manufacturing and sales 
particularly on the accuracy of labelling and licensing 
to protect the public health. Compulsory declaration of 
the contents by the manufacturer should be enforced to 
avoid endless cost-ineffective sampling by enforcement 
agencies. Any contradiction to such self-declared labels 
should be deemed as non-compliance under the law for 
deceptive labeling. Another worrying issue is that there 
is possibility of other dangerous drugs or alcohol to be 
misused by the act of vaping. Thus, e-cigarette devices 
should also be deemed as “utensils” under the original 
and revised version of the Dangerous Drugs Act 1952. 
In supporting the Endgame of tobacco in Malaysia in 
2045, there is an urgency for the government to come 
out with a legislation related to EC and strengthening 
its existing enforcements to prevent detrimental health 
effects arising from EC usage.
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